|Dr. Igor Gonda Ph.D.||Chief Exec. Officer, Pres and Exec. Director||438.68k||N/A||69|
|Ms. Nancy E. Pecota||Chief Financial Officer, VP of Fin. and Corp. Sec.||359.26k||N/A||57|
|Dr. Juergen Froehlich M.D., MBA, FCPh||Chief Medical Officer||424.17k||N/A||60|
|Dr. Robert A. Reed Ph.D.||VP of Regulatory CMC & Quality||N/A||N/A||56|
|Dr. David Cipolla Ph.D.||VP of Preclinical R&D||N/A||N/A||N/A|
Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. The companys lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq (ARD-3150) and Lipoquin (ARD-3100) that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis and cystic fibrosis. It is also developing inhaled ciprofloxacin formulations for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, as well as the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever, and inhaled anthrax. The company has collaboration agreements with Oregon State University and Grifols, S.A. Aradigm Corporation was founded in 1991 and is headquartered in Hayward, California.
Aradigm Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.